Business Context and Reporting Period
This summary covers the Form 10-Q for Cyclacel Pharmaceuticals, Inc. (trading as CYCC, expected to rename to Bio Green Med Solution, Inc. with ticker BGMS) for the quarterly and six-month periods ended June 30, 2025. The Company is a clinical-stage biopharmaceutical firm currently undergoing a strategic pivot. Key developments include the liquidation of its UK subsidiary (Cyclacel Limited) in January 2025, a change in control involving investor Datuk Dr. Doris Wong Sing Ee, and a pending reverse merger with FITTERS Diversified Berhad to acquire industrial assets. The Company has executed two reverse stock splits (1-for-16 and 1-for-15) in 2025.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $33,000 |
| Net Loss | $(1,399,000) | $(6,203,000) |
| Operating Expenses | $6,353,000 | $8,032,000 |
| Research & Development | $890,000 | $4,825,000 |
| General & Administrative | $5,463,000 | $3,207,000 |
| Cash and Cash Equivalents (End of Period) | $4,275,000 | $6,000,000 |
| Working Capital | $3,623,000 | $521,000 |
| Total Liabilities | $770,000 | $6,268,000 |
Note: The Net Loss for the six months ended June 30, 2025, includes a non-cash gain of approximately $4.95 million from the deconsolidation of the UK subsidiary.
Material Changes vs. Prior Period
- Deconsolidation of Subsidiary: The liquidation of Cyclacel Limited (UK) in January 2025 resulted in a $4.95 million gain on deconsolidation, significantly reducing the reported net loss compared to the prior year. This also eliminated the UK-based R&D costs for the fadraciclib program.
- Expense Shift: While total operating expenses decreased by approximately $1.7 million year-over-year, the composition shifted. R&D expenses dropped 82% due to the cessation of the fadraciclib program. Conversely, G&A expenses increased 70% ($2.3 million) driven by one-time costs related to changes in control, including $1.3 million in stock-based compensation and $0.7 million in D&O insurance.
- Liquidity Improvement: Current liabilities decreased from $6.27 million to $0.76 million, primarily due to the settlement of outstanding liabilities using proceeds from preferred stock issuances in early 2025.
- Capital Structure: The Company issued Series C, D, E, and F preferred stock and warrants in 2025, raising approximately $6.6 million net of expenses to fund operations and settle debts.
Guidance, Outlook, and Risks
- Going Concern: Management has disclosed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. Cash on hand ($4.3 million) is projected to fund operations only into the fourth quarter of 2025. Additional financing is required to avoid curtailing operations or filing for bankruptcy.
- Strategic Transaction: The Company is pursuing an Exchange Agreement with FITTERS Diversified Berhad. If closed, Cyclacel will acquire Fitters Sdn. Bhd., a Malaysian fire safety and real estate company, and rename to Bio Green Med Solution, Inc. Closing is expected by September 30, 2025.
- Operational Focus: The Company has narrowed its biopharmaceutical focus solely to the plogosertib (Plogo) clinical program. The fadraciclib program assets are being sold by the liquidator of the UK subsidiary.
- Legal Proceedings: On August 6, 2025, minority shareholder David Lazar filed a lawsuit against the Company and CEO Datuk Dr. Doris Wong Sing Ee, alleging breach of fiduciary duty and minority shareholder oppression, seeking approximately $12.5 million in damages. The Company intends to vigorously defend the claims.
- Regulatory Status: The Company regained compliance with Nasdaq equity requirements in February 2025 but remains under a Mandatory Panel Monitor for one year.
Investor Verification Checklist
- Transaction Closing: Verify the status of the Exchange Agreement with FITTERS Diversified Berhad and the likelihood of closing before the September 30, 2025 deadline.
- Capital Sufficiency: Confirm the timeline and certainty of additional equity financing required to bridge the gap beyond Q4 2025 if the strategic transaction does not close.
- Legal Exposure: Assess the potential financial impact of the pending lawsuit filed by David Lazar and the Company's ability to fund a legal defense.
- Asset Repurchase: Review the terms of the $0.3 million asset repurchase for the plogosertib program and the current status of the Phase 1/2 clinical trial.
- Stock Dilution: Analyze the impact of outstanding warrants (approx. 1.96 million shares) and convertible preferred stock (Series F) on future share count and ownership dilution.